Synaptogenix Inc (SNPX)

[donsker]

I think the poster's reference is to an article that came out right after the P1 study on safety with a secondary end point its effacey. When I spoke to IR last week, I asked if AF had followed up with him and he said no. He complained that AF referred to the lack of effacey in that trial by pulling this old article and without checking with Neurotrope. IR complained that former mgmnt made a statement of no results seen when there was only 1 dose given. Now apparently they've found some positive data on that, and either prior mgment was careless in that comment based on Alkon's review of data, or Alkon is being careless himself. Everything I see says Alkon is more than a straight shooter. Also, IR likened that secondary endpoint to testing Lipitor by taking 1 Lipitor, 1 time only, and then scouring data to see if it worked. I wish I had the link for the article.